OTS-412 + hydroxyurea

OTS-412 + hydroxyurea is an investigational combination therapy composed of **OTS-412**, a recombinant oncolytic vaccinia virus, and **hydroxyurea**, a ribonucleotide reductase inhibitor. OTS-412 is engineered to selectively infect and lyse tumor cells, stimulating antitumor immune responses and facilitating tumor apoptosis; hydroxyurea may enhance viral oncolysis by modulating host DNA synthesis and hematologic milieu. This combination is being studied primarily for use in patients with treatment-refractory solid tumors, aiming to improve efficacy over monotherapies and determine the optimal dosing of hydroxyurea for synergy with OTS-412[3]. OTS-412 is designed for tumor-selectivity and may trigger immune-mediated cytotoxicity following direct tumor cell infection[2][4]. Hydroxyurea is an established chemotherapeutic agent commonly used in hematological disorders, and in this context, it is repurposed as an immunomodulatory adjuvant. Current research evaluates safety, dosing, antitumor activity, immune effects, and pharmacokinetics in advanced solid tumors[1][3].

Other names

OTS-412 + HU